The maintenance of a Buy rating by B. Riley Securities indicates continued confidence in Viridian Therapeutics' potential. However, the reduction in the price target from $29 to $25 suggests a recalibration of expectations, possibly due to market conditions or company-specific factors not detailed in the news. This mixed signal could lead to short-term uncertainty among investors, balancing optimism with a more conservative valuation.